Seydi Enayatollah, Rasekh Hamid R, Salimi Ahmad, Mohsenifar Zhaleh, Pourahmad Jalal
Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Anticancer Agents Med Chem. 2016;16(12):1576-1586. doi: 10.2174/1871520616666160425110839.
hepatocellular carcinoma (HCC) is the third cause of mortality due to cancer throughout the world.
The main goal of the current research was to evaluate the selective toxicity of apigenin (APG) on hepatocytes and mitochondria obtained from the liver of HCC rats).
In this research, HCC induced by a single dose of diethylnitrosamine (DEN); 200 mg/kg, i.p, and 2-acetylaminofluorene (2-AAF) (0.02%, through dietary) for 14 days. For confirmation of HCC, histopathological evaluations and determination of serum concentrations of liver toxicity enzymes and specific liver cancer marker; alpha-fetoprotein (AFP) were performed. Then, cancerous and non- cancerous hepatocytes were isolated by using the collagen perfusion method. Eventually, mitochondria isolated from HCC and normal hepatocytes were tested for every eventual toxic effects of APG.
After confirmation of HCC, the results of this research showed that APG (10, 20 and 40 μM) increased mitochondrial parameters such as, mitochondrial membrane potential (MMP), reactive oxygen species (ROS) level, mitochondrial swelling and cytochrome c expulsion only in cancerous hepatocytes. Apoptotic effect of APG on HCC cells was confirmed by caspase-3 activation and Annexin V-FITC and PI double staining analysis.
These results propose the eligibility of the flavonoid APG as a complementary therapeutic agent for patients with hepatocellular carcinoma.
肝细胞癌(HCC)是全球癌症致死的第三大原因。
本研究的主要目的是评估芹菜素(APG)对肝癌大鼠肝脏来源的肝细胞和线粒体的选择性毒性。
在本研究中,通过腹腔注射单剂量的二乙基亚硝胺(DEN)(200 mg/kg)和经饮食给予2-乙酰氨基芴(2-AAF)(0.02%)诱导肝癌14天。通过组织病理学评估以及测定肝毒性酶的血清浓度和特异性肝癌标志物甲胎蛋白(AFP)来确认肝癌。然后,采用胶原灌注法分离癌性和非癌性肝细胞。最后,检测从肝癌细胞和正常肝细胞中分离出的线粒体对APG的各种潜在毒性作用。
在确认肝癌后,本研究结果表明,APG(10、20和40 μM)仅在癌性肝细胞中增加线粒体参数,如线粒体膜电位(MMP)、活性氧(ROS)水平、线粒体肿胀和细胞色素c释放。通过半胱天冬酶-3激活以及膜联蛋白V-异硫氰酸荧光素和碘化丙啶双染色分析证实了APG对肝癌细胞的凋亡作用。
这些结果表明黄酮类化合物APG有资格作为肝细胞癌患者的辅助治疗药物。